Managing Antipsychotic-induced Metabolic Syndrome

Naoko Morikawa and Loc Lam

Health System Sponsors: Aaron Miller, Sherri Borden and Stacey Murphy

Clay House

Progress Foundation

ADVANCING HEN23448 BEWIDENCE-Based Project Planning I&II



Project Goals

Goal: Implement a trial SOP

Measures

Process measures: Successful implementation

Outcome measures: Residents' metabolic syndrome data & PHQ-2

Balancing measures: Same as process

ADVANCING HEALTH WORLDWIDE™



Background and Significance of Problem

Antipsychotic side effects: significant weight gain, dyslipidemia, and diabetes

 \rightarrow cardio vascular diseases (ADA, 2004).



ADVANCING HEALTH WORLDWIDE™

Current Practice at Agency

Current practice at Clay House of Progress Foundation

- Screening for metabolic syndrome on residents' admission.
- If the residents reject, the data not necessarily collected.
- No SOP for monitoring metabolic syndrome on residents with antipsychotics



Test of Change Intervention and Implementation

Monthly : BMI, VS and the number of successful protocol use monitoring

The baseline & 3 month : monthly + labs, glucose, PHQ-2

All implemented by the PMHNP at Clay House



Data Analysis and Results

			date	24-Jun	4-Sep	9-Oct	18-Nov	4-Dec
Legend:	MIA		wt	no data	265.2	266.6	269.8	
	Records		glucose	no data	refused			
	Marked cl	nanges	bp	132/48 (64	148/92	140/92	140/80	
	Pending		waist circ	no data	refused	50	49.5	
	n/a		Labs	no data	refused			
			date		4-Sep	9-Oct	18-Nov	4-Dec
			wt	no data	refused		refused	
			glucose	no data	refused			
			bp	no data	140/58		132/68	
			waist circ	no data	41.75		42	
			Labs	no data	refused			
			date	10-Jun	4-Sep	9-Oct	18-Nov	4-De
			wt	234 lbs	116.2 lbs	163.2 lbs	165 lbs	
			glucose	ref				
			bp	118/78	118/70	110/72	115/68	
			waist circ	no data	33.12	33	33.5	
			Labs	no data	refused			
			date	24-Jun	4-Sep	9-Oct	18-Nov	4-De
			wt	no data	MIA		220	
			glucose	no data				
			bp	138/62 (64	l) 18 rr		126/62	
			waist circ	no data			. 42.5	
			Labs	no data				
	date	5-Jun	10-Jun	13-Aug	4-Sep	9-Oct	18-Nov	4-De
	wt	no data	240 lbs	195 lbs	231.6	227.4	229.8	. 50
	glucose	no data	270105	200 100	refused	227.4	223.0	
	hn	no data	122/00/00	111/72	120/06	120/90	126/92	
	waist eire	no data	122/00 (80	111/75	130/00	130/00	20/02	
	waist circ	no data			40	38.5	39.5	
	Labs	no data			refused			

- Data are inconsistent, incomplete, or suboptimal
- Increased clinician awareness
- PDSA #2: Proposals to Progress Foundation
 - SOPs for data collection upon admission, ongoing care, and transferring care.
 - Audit with incentive for high compliance rates.



Discussion and Conclusion

Lesson learned:

 No single person at fault. Patient's nonadherence, lack of education, and personal needs versus clinicians' allotted time, lack of follow through (system error), and lack of resources (no guidelines).

Applications:

- SOPs for more complete data collection on admission, in-care and discharge.
 - Will propose plan to Progress House staff and ask that they continue this project.



Implications for Evidence-based Practice and Policy

By creating a standard operating procedure to guide clinicians in management of patients being administered antipsychotics, this will allow clinicians to tailor individualized treatment plans based on holistic objective data.

Increasing awareness may improve satisfaction and adherence from both clinicians and patients. Patients may be more likely to abide to treatment plans if they know how their health are being affected. Clinicians can provide optimal care by intervening upon noted changes (before symptoms become more problematic).

Administratively, inappropriate use and poor assessment of antipsychotic use leads to many other comorbidities, hence, increase system's cost of care.



Acknowledgements and References

Thank you to Stacey Murphy, PMHNP for being our direct line of contact at Clay House.

Kudos to Aaron Miller, PMHNP and Sherri Borden, ANP for getting the ball rolling.

Clay House's residents for their participation in this project.

American Diabetes Association. (2014). Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease. Retrieved from http://professional.diabetes.org/admin/UserFiles/file/CE/AntiPsych%20Meds/Professional%20Tool%20%231(1).pdf

Morrato, E., Newcomer, J., Kamat, S., Baser, O., Harnett, J., & Cuffel, B. (2009). Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681020/

Lieberman, J. (2004). Metabolic Changes Associated With Antipsychotic Use. Primary Care Companion Journal Clinical Psychiatry, 6 (pg8-13)

Owen, R., Drummond, K., Viverito, K., Marchant, K., Pope, S., Smith, J., & Landes, R. (2013). Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation. Implementation Science. Retrieved from http://www.implementationscience.com/content/8/1/120

